| Identification | Back Directory | [Name]
JI-101 | [CAS]
900573-88-8 | [Synonyms]
JI-101
CS-2268
CGI 1842
JI101;JI 101
Pazopanib Impurity 66
1-[1-[(2-Aminopyridin-4-yl)methyl]-1H-indol-4-yl]-3-(5-bromo-2-methoxyphenyl)urea
Urea, N-[1-[(2-amino-4-pyridinyl)methyl]-1H-indol-4-yl]-N'-(5-bromo-2-methoxyphenyl)- | [EINECS(EC#)]
604-604-1 | [Molecular Formula]
C22H20BrN5O2 | [MDL Number]
MFCD26142530 | [MOL File]
900573-88-8.mol | [Molecular Weight]
466.33 |
| Chemical Properties | Back Directory | [Boiling point ]
606.9±55.0 °C(Predicted) | [density ]
1.50±0.1 g/cm3(Predicted) | [storage temp. ]
Hygroscopic, -20°C Freezer, Under inert atmosphere | [solubility ]
DMSO (Slightly), Methanol (Slightly, Heated) | [form ]
Solid | [pka]
13.25±0.70(Predicted) | [color ]
Pale Brown |
| Hazard Information | Back Directory | [Uses]
JI-?101 is VEGFR2 inhibitor. It can be used as analyte in pharmacological activity and analytical study of assay methodologies and perspectives for quantitation of VEGFR2 inhibitors such as sunitinib, sorafenib, pazopanib and JI-101 which were involved in treatment of cancer in human and animal models including mouse. | [in vivo]
JI-101excreted through bile along with its mono- and di-hydroxy metabolites. Following oral administration, JI-101 is rapidly absorbed, reaching Cmax within 2?h. The t1/2 of JI-101 with intravenous and oral route is found to be 1.75±0.79 and 2.66±0.13?h, respectively. The Cl and Vd by intravenous route for JI-101 are found to be 13.0±2.62?mL/min/kg and 2.11±1.42?L/kg, respectively. The tissue distribution of JI-101 is extensive with rapid and preferred uptake into lung tissue. Overall, the oral bioavailability of JI-101 is 55% and the primary route of elimination for JI-101 is feces[1]. | [IC 50]
VEGFR2; PDGFRβ | [storage]
Store at -20°C |
|
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
www.yuhua99.com/ShowSupplierProductsList15748/0_EN.htm |
|